Compare Exelixis Inc. Common Stock (EXEL) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Exelixis Inc. Common Stock vs Eli Lilly And Co — how do they compare? Exelixis Inc. Common Stock trades at $59.43 (market cap $14.48B), while Eli Lilly And Co trades at $1,166.02 (market cap $1.06T). The key difference: Eli Lilly And Co is far larger — about 73.2× Exelixis Inc. Common Stock's market cap, and Eli Lilly And Co pays a 0.58% dividend while Exelixis Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Exelixis Inc. Common Stock for 0 Days and Eli Lilly And Co for 93 Days on average.
| EXEL | LLY | |
|---|---|---|
Market Cap | $14.48B | $1.06T |
Volume | 2,374,774 | 2,297,239 |
Sector | Health | Health |
52-Week High | $59.13 | $1.28K |
52-Week Low | $34.54 | $799.57 |
Typical Hold Time | 0 Days | 93 Days |
Enterprise Value | $13.81B | $1.11T |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Eli Lilly (LLY) trades at $1,169.93, up 1.07% on the day, with a bullish technical signal and strong fundamental momentum. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $8.38 exceeding the $6.40 estimate. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Positive news flow highlights promising pipeline updates in weight-loss and diabetes drugs, reinforcing growth prospects.
Outlook remains favorable given dominant market position and innovation pipeline, though high valuation multiples pose a risk. Analyst consensus is strongly bullish with a $1,340 price target. Key risks include competitive pressures and execution challenges in scaling production to meet demand for blockbuster therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Exelixis Inc. Common Stock
Exelixis develops and commercializes medicines for cancer. Its research focuses on targeted therapies for oncology.
Read more on EXEL →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
